BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

TaiGen, Warner Chilcott deal

TaiGen received exclusive, worldwide rights to develop and commercialize Warner Chilcott's nemonoxacin. The oral formulation of a non-fluorinated quinolone antibiotic topoisomerase inhibitor is in a Phase III trial in Asia, which is slated to complete...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >